PseudoFab-based multispecific binding proteins

Patent metadata

Field	Value
Publication number	US-11739160-B2
Application number	US-201916725224-A
Country	US
Kind code	B2
Filing date	Dec 23, 2019
Priority date	Dec 24, 2018
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

First claim

The invention claimed is:

1. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein the VLX/VHX pair is selected from the group consisting of:
(i) VLX comprising an amino acid sequence of SEQ ID NO: 76 and VHX comprising an amino acid sequence of SEQ ID NO: 77;
ii) VLX comprising an amino acid sequence of SEQ ID NO: 76 and VHX comprising an amino acid sequence of SEQ ID NO: 78; and
iii) VLX comprising an amino acid sequence of SEQ ID NO: 76 and VHX comprising an amino acid sequence of SEQ ID NO: 79.

2. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein:

(a) the VHX comprises one or more inactivating mutations of Y33A, R50E, R59E, and Y105A as set forth in SEQ ID NO: 2, and a cysteine substitution of G44C as set forth in SEQ ID NO: 2; and
(b) the VLX comprises a cysteine substitution of Q100C as set forth in SEQ ID NO: 1.

3. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein:

(a) the VHX comprises a cysteine substitution of G44C as set forth in SEQ ID NO: 3; and
(b) the VLX comprises a cysteine substitution of Q100C as set forth in SEQ ID NO: 1.

4. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein:

(a) the VHX comprises a cysteine substitution of G44C as set forth in SEQ ID NO: 4; and
(b) the VLX comprises a cysteine substitution of Q100C as set forth in SEQ ID NO: 1.

5. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein:
(a) the VHX comprises a cysteine substitution of G44C as set forth in SEQ ID NO: 5; and
(b) the VLX comprises a cysteine substitution of Q100C as set forth in SEQ ID NO: 1.

6. A binding protein comprising:
at least one pseudoFab portion comprising
(1) a first VL domain (VLa) paired with a first VH domain (VHa) to form a first functional antigen binding site that binds target antigen A; and
(2) a first stabilized knockout VH domain (VHX) paired with a first stabilized knockout VL domain (VLX) to form a first stabilized knockout domain, wherein the VLX/VHX pair is selected from the group consisting of:
(i) a VLX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 76, and comprising a cysteine substitution of Q100C, and
a VHX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 77, and comprising amino acid substitutions Y33A, R50E, R59E, and Y105A and a cysteine substitution of G44C;

ii) a VLX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 76, and comprising a cysteine substitution of Q100C, and
a VHX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 78, and comprising amino acid substitutions R50E and R59E and a cysteine substitution of G44C; and

iii) a VLX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 76, and comprising a cysteine substitution of Q100C, and
a VHX comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 79, and comprising amino acid substitutions Y33A and Y105A and a cysteine substitution of G44C.

7. The binding protein of claim 1 , wherein the binding protein comprises separate proteins chains selected from one of the following groups:
(a) VHa-CH1-L1-VHb-L2-VHX and VLa-CL and VLb-L3-VLX;
(b) VHa-L2-VHX-L1-VHb-CH1 and VLa-L3-VLX and VLb-CL;
(c) VHa-CH1-L1-VHa-CH1 and VHb-L2-VHX-L3-VHb-L4-VHX and two chains VLb-L5-VLX and two chains VLa-CL;
wherein the chains of (a) and (b) can be present once or twice, and
wherein L1, L2, L3, L4 and L5 are linkers, which are independently the same or different.

8. The binding protein of claim 1 , wherein the binding domain comprises independently one or two first pseudoFab portion(s) and one or two first Fab portion(s).

9. The binding protein of claim 1 , wherein:
(1) the first pseudoFab portion comprises a first polypeptide chain having a structure represented by the formula:
N-VHa-L1-VHX-C  (Ia)

and a second polypeptide chain having a structure represented by the formula:
N-VLa-L2-VLX-C  (IIa)

wherein L1 and L2 are linkers, which can independently be present or absent, and wherein N and C represent the N- and C-terminal ends, respectively;
(2) the first pseudoFab portion comprises of a first polypeptide chain having a structure represented by the formula:
N-VHX-L1-VHa-C  (Ib)

and a second polypeptide chain having a structure represented by the formula:
N-VLX-L2-VLa-C  (IIb)

wherein L1 and L2 are linkers, which can independently be present or absent, and wherein N and C represent the N- and C-terminal ends, respectively;
(3) the first pseudoFab portion comprises of a first polypeptide chain having a structure represented by the formula:
N-VLa-L1-VHX-C  (Ic)

and a second polypeptide chain having a structure represented by the formula:
N-VHa-L2-VLX-C  (IIc)

wherein L1 and L2 are linkers, which can independently be present or absent, and wherein N and C represent the N- and C-terminal ends, respectively; or
(4) the first pseudoFab portion comprises of a first polypeptide chain having a structure represented by the formula:
N-VHX-L1-VLa-C  (Id)

and a second polypeptide chain having a structure represented by the formula:
N-VLX-L2-VHa-C  (IId)

wherein L1 and L2 are linkers, which can independently be present or absent, and wherein N and C represent the N- and C-terminal ends, respectively.

10. The binding protein claim 1 , further comprising one or more additional binding domains operably linked to an N- or C-terminus of the binding protein.

11. The binding protein claim 1 , wherein the one or more additional binding domains are operably linked to N-terminus of the first or second pseudoFab portion.

12. The binding protein of claim 2 , wherein the binding protein comprises separate proteins chains selected from one of the following groups:
(a) VHa-CH1-L1-VHb-L2-VHX and VLa-CL and VLb-L3-VLX;
(b) VHa-L2-VHX-L1-VHb-CH1 and VLa-L3-VLX and VLb-CL;
(c) VHa-CH1-L1-VHa-CH1 and VHb-L2-VHX-L3-VHb-L4-VHX and two chains VLb-L5-VLX and two chains VLa-CL;
wherein the chains of (a) and (b) can be present once or twice, an

Assignees

• Sanofi Sa

Inventors

• Beil Christian
• Engel Karl-Christian
• Hessler Gerhard
• Hoelper Soraya
• Lange Christian
• Langer Thomas
• Lemoine Cendrine
• Leuschner Wulf-Dirk
• Bruderle Sevim Ozgur
• Rao Ercole
• Spindler Nadja
• Weil Sandra

Classifications

• C07K16/32 Primary

  against translation products of oncogenes · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/522

  CH1 domain · CPC title

• C07K2317/524

  CH2 domain · CPC title

• C07K2317/526

  CH3 domain · CPC title